APGN
Closed
Apexigen Inc.
0.385
0.000 (0.00%)
Last Update: 01 Sep 2023 16:30:00
Yesterday: 0.385
Day's Range: 0.385 - 0.385
Send
sign up or login to leave a comment!
When Written:
0.5
Apexigen Inc. is a biopharmaceutical company that develops immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate, APX005M, is a monoclonal antibody that targets CD40, a protein on the surface of immune cells. APX005M is being evaluated in clinical trials for the treatment of various types of cancer, including pancreatic cancer, melanoma, and non-small cell lung cancer. Apexigen also has a pipeline of other immunotherapy candidates, including APX005M-002, a combination therapy of APX005M and chemotherapy for pancreatic cancer, and APX005M-003, a combination therapy of APX005M and a PD-1 inhibitor for advanced solid tumors. The company was founded in 2002 and is headquartered in San Carlos, California.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








